DexCom, Inc. (NASDAQ:DXCM) – William Blair increased their Q4 2017 earnings estimates for shares of DexCom in a report released on Tuesday, according to Zacks Investment Research. William Blair analyst M. Kaczor now anticipates that the medical device company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.02. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.56) EPS.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%.
A number of other research analysts also recently issued reports on DXCM. BidaskClub cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Piper Jaffray Companies reissued a “buy” rating and issued a $87.00 price objective on shares of DexCom in a research report on Thursday, September 28th. Barclays reissued a “hold” rating and issued a $60.00 price objective on shares of DexCom in a research report on Monday, January 8th. Northland Securities began coverage on DexCom in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 price objective for the company. Finally, Leerink Swann reissued a “buy” rating and issued a $57.00 price objective (down previously from $85.00) on shares of DexCom in a research report on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. DexCom presently has an average rating of “Buy” and a consensus target price of $68.50.
DexCom (NASDAQ DXCM) opened at $56.32 on Thursday. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32. The stock has a market capitalization of $4,902.21, a price-to-earnings ratio of -98.81 and a beta of 0.31. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.
In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $58.85, for a total transaction of $353,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,140 shares of company stock valued at $2,158,576. 1.70% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in shares of DexCom by 12.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the last quarter. Ithaka Group LLC raised its stake in shares of DexCom by 0.9% during the 2nd quarter. Ithaka Group LLC now owns 81,416 shares of the medical device company’s stock valued at $5,956,000 after buying an additional 703 shares during the last quarter. Advisor Group Inc. raised its stake in shares of DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of DexCom by 0.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock valued at $6,247,000 after buying an additional 1,095 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in shares of DexCom by 15.2% during the 3rd quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock valued at $422,000 after buying an additional 1,129 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/18/equities-analysts-issue-forecasts-for-dexcom-inc-s-q4-2017-earnings-dxcm.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Get a free copy of the Zacks research report on DexCom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.